2020 |
Bond DR, Kahl R, Brzozowski JS, Jankowski H, Naudin C, Pariyar M, et al., 'Tetraspanin CD9 is regulated by MiR-518f-5p and functions in breast cell migration and in vivo tumor growth', Cancers, 12 (2020) [C1]
|
|
Nova |
2018 |
Bond DR, Naudin C, Carroll AP, Goldie BJ, Brzozowski JS, Jankowski HM, et al., 'miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion', ONCOTARGET, 9 1980-1991 (2018) [C1]
|
|
Nova |
2017 |
Karimi E, Faraji H, Hamidi Alamdari D, Souktanloo M, Mojarrad M, Ashman LK, Mashkani B, 'Overexpression of functional human FLT3 ligand in Pichia pastoris', Applied Biochemistry and Microbiology, 53 421-428 (2017) [C1]
|
|
Nova |
2017 |
Qiao Y, Tam JKC, Tan SSL, Tai YK, Chin CY, Stewart AG, et al., 'CD151, a laminin receptor showing increased expression in asthmatic patients, contributes to airway hyperresponsiveness through calcium signaling', Journal of Allergy and Clinical Immunology, 139 82-92.e5 (2017) [C1]
Background Airway smooth muscle (ASM) contraction underpins airway constriction; however, underlying mechanisms for airway hyperresponsiveness (AHR) remain incompletely defined. C... [more]
Background Airway smooth muscle (ASM) contraction underpins airway constriction; however, underlying mechanisms for airway hyperresponsiveness (AHR) remain incompletely defined. CD151, a 4-transmembrane glycoprotein that associates with laminin-binding integrins, is highly expressed in the human lung. The role of CD151 in ASM function and its relationship to asthma have yet to be elucidated. Objective We sought to ascertain whether CD151 expression is clinically relevant to asthma and whether CD151 expression affects AHR. Methods Using immunohistochemical analysis, we determined the expression of CD151 in human bronchial biopsy specimens from patients with varying asthma severities and studied the mechanism of action of CD151 in the regulation of ASM contraction and bronchial caliber in¿vitro, ex¿vivo, and in¿vivo. Results The number of CD151+ ASM cells is significantly greater in patients with moderate asthma compared with those in healthy nonasthmatic subjects. From loss- and gain-of-function studies, we reveal that CD151 is required for and enhances G protein¿coupled receptor (GPCR)¿induced peak intracellular calcium release, the primary determinant of excitation-contraction coupling. We show that the localization of CD151 can also be perinuclear/cytoplasmic and offer an explanation for a novel functional role for CD151 in supporting protein kinase C (PKC) translocation to the cell membrane in GPCR-mediated ASM contraction at this site. Importantly, CD151-/- mice are refractory to airway hyperreactivity in response to allergen challenge. Conclusions We identify a role for CD151 in human ASM contraction. We implicate CD151 as a determinant of AHR in vivo, likely through regulation of GPCR-induced calcium and PKC signaling. These observations have significant implications in understanding the mechanism for AHR and the efficacy of new and emerging therapeutics.
|
|
Nova |
2017 |
Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
|
|
Nova |
2016 |
Mashkani B, Tanipour MH, Saadatmandzadeh M, Ashman LK, Griffith R, 'FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies', European Journal of Pharmacology, 776 156-166 (2016) [C1]
Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic targe... [more]
Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target for small molecule kinase inhibitors. In this study, protein-ligand interactions between FLT3 and kinase inhibitors (CEP701, PKC412, sunitinib, imatinib and dasatinib) were obtained through homology modelling and molecular docking. A cellular system for experimental testing of the inhibitors was also established by expressing wildtype and internal tandem duplication mutant FLT3 (FLT3-WT and FLT3-ITD) in FDC-P1 cells. Imatinib and dasatinib could not be docked into any of the FLT3 models, consistent with their lack of activity in the experimental assays. CEP701, PKC412 and sunitinib interacted with the ATP-binding pocket of FLT3, forming H-bonds with Cys694 and Glu692. Based on the EC50 values in the cell proliferation assay, CEP701 was the most potent inhibitor; sunitinib and PKC412 were ranked second and third, respectively. Sunitinib was the most selective inhibitor, followed by PKC421 and CEP701. The potency of sunitinib and to a lesser extent CEP701 in inhibition of FLT3 autophosphorylation was lower than the cell proliferation inhibition, indicating that inhibition of FLT3 downstream proteins may contribute to the cellular effects. It was shown in this study that the docking procedure was able to differentiate FLT3 inhibitors from ineffective compounds. Additionally, interaction with the phosphate binding region in the ATP-binding pocket increased potency at the cost of selectivity. These findings can be applied in designing highly effective and selective inhibitors for FLT3 and other related kinases.
|
|
Nova |
2016 |
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7 47465-47478 (2016) [C1]
Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leuke... [more]
Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+ BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+ cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.
|
|
Nova |
2015 |
Makkawi M, Moheimani F, Alserihi R, Howells D, Wright M, Ashman L, Jackson DE, 'A complementary role for tetraspanin superfamily member CD151 and ADP purinergic P2Y12 receptor in platelets.', Thromb Haemost, 114 1004-1019 (2015) [C1]
|
|
Nova |
2014 |
Mashkani B, Griffith R, Ashman L, 'Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants', IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 17 867-873 (2014) [C1]
|
|
Nova |
2014 |
Roselli S, Kahl RGS, Copeland BT, Naylor MJ, Weidenhofer J, Muller WJ, Ashman LK, 'Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model', BMC Cancer, 14 (2014) [C1]
Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes containing, for example, integrins, growth factor receptors and matrix metal... [more]
Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes containing, for example, integrins, growth factor receptors and matrix metalloproteases, and modify their functions in cell adhesion, migration and transmembrane signaling. CD151 is part of the tetraspanin family and it forms tight complexes with ß1 and ß4 integrins, both of which have been shown to be required for tumorigenesis and/or metastasis in transgenic mouse models of breast cancer. High levels of the tetraspanin CD151 have been linked to poor patient outcome in several human cancers including breast cancer. In addition, CD151 has been implicated as a promoter of tumor angiogenesis and metastasis in various model systems.Methods: Here we investigated the effect of Cd151 deletion on mammary tumorigenesis by crossing Cd151-deficient mice with a spontaneously metastasising transgenic model of breast cancer induced by the polyoma middle T antigen (PyMT) driven by the murine mammary tumor virus promoter (MMTV).Results: Cd151 deletion did not affect the normal development and differentiation of the mammary gland. While there was a trend towards delayed tumor onset in Cd151 -/- PyMT mice compared to Cd151 +/+ PyMT littermate controls, this result was only approaching significance (Log-rank test P-value =0.0536). Interestingly, Cd151 deletion resulted in significantly reduced numbers and size of primary tumors but did not appear to affect the number or size of metastases in the MMTV/PyMT mice. Intriguingly, no differences in the expression of markers of cell proliferation, apoptosis and blood vessel density was observed in the primary tumors.Conclusion: The findings from this study provide additional evidence that CD151 acts to enhance tumor formation initiated by a range of oncogenes and strongly support its relevance as a potential therapeutic target to delay breast cancer progression. © 2014 Roselli et al.; licensee BioMed Central Ltd.
|
|
Nova |
2013 |
Copeland BT, Bowman MJ, Boucheix C, Ashman LK, 'Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner', International Journal of Cancer, 133 1803-1812 (2013) [C1]
Prostate cancer is an extremely heterogeneous disease; patients that do progress to late-stage metastatic prostate cancer have limited treatment options, mostly palliative. Molecu... [more]
Prostate cancer is an extremely heterogeneous disease; patients that do progress to late-stage metastatic prostate cancer have limited treatment options, mostly palliative. Molecules involved in the metastatic cascade may prove beneficial in stratifying patients to assign appropriate treatment modalities and may also prove to be therapeutic antimetastatic targets. The tetraspanin group of molecules are integral membrane proteins that associate with motility-related proteins such as integrins. Clinical studies have mostly shown that reduced expression levels of the tetraspanin CD9 are correlated with tumour progression in a range of cancers. Furthermore, functional studies have shown CD9 to be involved in cell motility and adhesion and that it may influence metastasis. The effects of endogenous CD9 on prostate cancer initiation and progression were analysed by crossing a Cd9-/- (KO) murine model with a model of de novo developing and spontaneously metastasising prostate cancer, namely the transgenic adenocarcinoma of mouse prostate model. Our study demonstrates for the first time that ablation of Cd9 had no detectable effect on de novo primary tumour onset, but did significantly increase metastasis to the liver but not the lungs. What's new? The ability to distinguish between prostate tumors that are more or less likely to spread could facilitate decisions regarding treatment options for patients. A promising marker for such distinction is the tetraspanin protein CD9, which in experimental studies has been linked to metastasis. Here, Cd9 genetic ablation in the well-characterized transgenic adenocarcinoma of mouse prostate (TRAMP) model reveals an association between loss of Cd9 expression and increased incidence of metastases to the liver but not the lung. In contrast, Cd9 ablation did not affect primary prostate tumor initiation. The findings suggest that Cd9 acts as a suppressor of metastasis. Copyright © 2013 UICC.
|
|
Nova |
2013 |
Ashman LK, 'Renal disease as a potential compounding factor in carcinogenesis experiments with Cd151-null mice', ONCOGENE, 32 4457-4457 (2013) [C3]
|
|
Nova |
2013 |
Mashkani B, Odell AF, Byrnes EM, Griffith R, Ashman LK, 'Expression of biologically active human colony stimulating factor-1 in Pichia pastoris', Protein Expression and Purification, 88 93-97 (2013) [C1]
|
|
Nova |
2013 |
Ashman LK, Griffith R, 'Therapeutic targeting of c-KIT in cancer', EXPERT OPINION ON INVESTIGATIONAL DRUGS, 22 103-115 (2013) [C1]
|
|
Nova |
2013 |
Copeland BT, Bowman MJ, Ashman LK, 'Genetic Ablation of the Tetraspanin CD151 Reduces Spontaneous Metastatic Spread of Prostate Cancer in the TRAMP Model', MOLECULAR CANCER RESEARCH, 11 95-105 (2013) [C1]
|
|
Nova |
2011 |
Ashman LK, 'Cell line models identify different sensitivity of mutant forms of c-KIT to kinase inhibitory drugs and predict the response of patients to therapy', Molecular Cancer Therapeutics, 10 2032-2033 (2011) [C3]
|
|
|
2011 |
Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
|
|
|
2010 |
Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
|
|
Nova |
2010 |
Mashkani B, Griffith R, Ashman LK, 'Colony stimulating factor-1 receptor as a target for small molecule inhibitors', Bioorganic & Medicinal Chemistry, 18 1789-1797 (2010) [C1]
|
|
Nova |
2010 |
Ang J, Fang B-L, Ashman LK, Frauman AG, 'The migration and invasion of human prostate cancer cell lines involves CD151 expression', Oncology Reports, 24 1593-1597 (2010) [C1]
|
|
Nova |
2009 |
Orlowski E, Chand R, Yip J, Wong C, Goschnick MW, Wright MD, et al., 'A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo', Journal of Thrombosis and Haemostasis, 7 2074-2084 (2009) [C1]
|
|
Nova |
2009 |
Weidenhofer JC, Ashman LK, 'CD151 (CD151 molecule (Raph blood group))', Atlas of Genetics and Cytogenetics in Oncology and Haematology, - - (2009) [C1]
|
|
Nova |
2009 |
Protty MB, Watkins NA, Colombo D, Thomas SG, Heath VL, Herbert JMJ, et al., 'Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains', Biochemical Journal, 417 391-400 (2009) [C1]
|
|
Nova |
2009 |
Sheng K-C, Van Spriel AB, Gartlan KH, Sofi M, Apostolopoulos V, Ashman LK, Wright MD, 'Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC', European Journal of Immunology, 39 50-55 (2009) [C1]
|
|
Nova |
2008 |
Baleato R, Guthrie PL, Gubler M-C, Ashman LK, Roselli SM, 'Deletion of Cd151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane', American Journal of Pathology, 173 927-937 (2008) [C1]
|
|
Nova |
2008 |
Foster RC, Byrnes EM, Meldrum C, Griffith R, Ross G, Upjohn E, et al., 'Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT', British Journal of Dermatology, 159 1160-1169 (2008) [C1]
|
|
Nova |
2008 |
Geary SM, Cowin AJ, Copeland BT, Baleato R, Miyazaki K, Ashman LK, 'The role of the tetraspanin CD151 in primary keratinocyte and fibroblast functions: Implications for wound healing', Experimental Cell Research, 314 2165-2175 (2008) [C1]
|
|
Nova |
2008 |
Baldwin G, Novitskaya V, Sadej R, Pochec E, Litynska A, Hartmann C, et al., 'Tetraspanin CD151 regulates glycosylation of alpha 3 beta 1 integrin', Journal of Biological Chemistry, 283 35445-35454 (2008) [C1]
|
|
Nova |
2008 |
Yamada M, Tamura Y, Sanzen N, Sato-Nishiuchi R, Hasegawa H, Ashman LK, et al., 'Probing the interaction of tetraspanin CD151 with integrin alpha 3 beta 1 using a panel of monoclonal antibodies with distinct reactivities toward the CD151-integrin alpha 3 beta 1 complex', Biochemical Journal, 415 417-427 (2008) [C1]
|
|
Nova |
2007 |
Young SM, Cambareri AC, Odell AF, Geary SM, Ashman LK, 'Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor', Cellular Signalling, 19 2572-2581 (2007) [C1]
|
|
|
2007 |
Roberts KG, Odell AF, Byrnes EM, Baleato R, Griffith R, Lyons AB, Ashman LK, 'Resistance to c-KIT kinase inhibitors conferred by V654A mutation', Molecular Cancer Therapeutics, 6 1159-1166 (2007) [C1]
|
|
|
2006 |
Young SM, Cambareri AC, Ashman LK, 'Role of c-KIT expression level and phosphatidylinositol 3-kinase activation in survival and proliferative responses of early myeloid cells', Cellular Signalling, 18 608-620 (2006) [C1]
|
|
|
2006 |
Griffith R, Brown MN, McCluskey A, Ashman LK, 'Small molecule inhibitors of protein kinases in cancer - How to overcome resistance', Mini-Reviews in Medicinal Chemistry, 6 1101-1110 (2006) [C1]
|
|
Nova |
2006 |
Cowin AJ, Adams D, Geary SM, Wright MD, Jones JCR, Ashman LK, 'Wound healing is defective in mice lacking tetraspanin CD151', Journal of Investigative Dermatology, 126 680-689 (2006) [C1]
|
|
Nova |
2006 |
Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS, 'A critical role for tetraspanin CD151 in alpha 381 and alpha 684 integrin-dependent tumor cell functions on Laminin-5', Molecular Biology of the Cell, 17 2707-2721 (2006) [C1]
|
|
|
2005 |
Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, et al., 'An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development', Cancer Research, 65 9633-9636 (2005) [C1]
|
|
Nova |
2005 |
Nixon B, Paul JW, Spiller CM, Attwell-Heap AG, Ashman LK, Aitken RJ, 'Evidence for the involvement of PECAM-1 in a receptor mediated signal-transduction pathway regulating capacitation-associated tyrosine phosphorylation in human spermatozoa', Journal of Cell Science, 118 4865-4877 (2005) [C1]
|
|
Nova |
2005 |
Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, et al., 'Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: Impact on cell motility', Clinical Cancer Research, 11 2840-2852 (2005) [C1]
|
|
|
2005 |
Ang J, Lijovic M, Frauman AG, Ashman LK, Kan K, 'Low grade primary prostate cancer (vol 13, pg 1717, 2004)', CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 14 553-553 (2005)
|
|
|
2005 |
Ang J, Lijovic M, Frauman AG, Ashman LK, Kahn K, 'Erratum: CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: A new prognostic indicator? (Cancer Epidemiology Biomarkers and Prevention (November 2004) 13, 11 (1717-1721))', Cancer Epidemiology Biomarkers and Prevention, 14 553 (2005) |
|
|
2004 |
Lau L-M, Wee JL, Wright MD, Moseley GW, Hogarth PM, Ashman LK, Jackson DE, 'The tetraspanin superfamily member CD151 regulates outside-in integrin alpha IIb Beta 3 signaling and platelet function', Blood, 104 2368-2375 (2004) [C1]
|
|
|
2004 |
Moseley GW, Lau L-M, Sheng K-C, Apostolopoulos V, Stanley EG, Jackson DE, et al., 'Characterization of Mice Lacking the Tetraspanin Superfamily Member CD151', Molecular and Cellular Biology, 24 5978-5988 (2004) [C1]
|
|
Nova |
2004 |
Ang J, Lijovic M, Ashman LK, Kan K, Frauman A, 'CD151 Protein Expression Predicts the Clinical Outcome of Low-Grade Primary Prostate Cancer Better than Histologic Grading: A New Prognostic Indicator?', Cancer Epidemiology, Biomarkers & Prevention, 13 1717-1721 (2004) [C1]
|
|
|
2004 |
Foster RC, Griffith R, Ferrao PT, Ashman LK, 'Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase', Journal of Molecular Graphics and Modelling, 23 139-152 (2004) [C1]
|
|
Nova |
2003 |
Chattopadhyay N, Wang Z, Ashman LK, Brady-Kalnay SM, Kreidberg JA, 'Alpha3 beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPu expression and cell-cell adhesion', The Journal of Cell Biology, 163 1351-1362 (2003) [C1]
|
|
|
2003 |
Charrin S, Manie S, Billard M, Ashman LK, Gerlier D, Boucheix C, Rubinstein E, 'Multiple levels of interactions within the tetraspanin web', Biochemical and Biophysical Research Communications, 304 107-112 (2003) [C1]
|
|
|
2003 |
Thai LM, Ashman LK, Harbour SN, Hogarth M, Jackson D, 'Physical proximity and functional interplay of PECAM-1 with the Fc receptor FcyRIIa on the platelet plasma membrane', Blood, 102 3637-3645 (2003) [C1]
|
|
|
2003 |
Ferrao PT, Frost MJ, Siah SP, Ashman LK, 'Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro', Blood, 102 4499-4503 (2003) [C1]
|
|
|
2003 |
Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK, Ronnstrand L, 'Src Family Kinases Are Involved in the Differential Signaling from Two Splice Forms of c-Kit', The Journal of Biological Chemistry, 278 9159-9166 (2003) [C1]
|
|
Nova |
2003 |
Ferrao PT, Gonda T, Ashman LK, 'Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver', Leukemia Research, 27 547-555 (2003) [C1]
|
|
|
2003 |
To LB, Bashford J, Durrant S, Macmillan J, Schwarer AP, Prince HM, et al., 'Successful mobilisation of peripheral blood stem cell after addition of ancestim (stem cell factor) in patients who had failed a prior mobilisation with filgrastim (granulocyte colony stimulating factor) alone or with chemotherapy plus filgrastim', Bone Marrow Transplantation, 31 371-378 (2003) [C1]
|
|
|
2002 |
Ashman LK, 'CD151', Journal of Biological Regulators and Homeostatic Agents, 16 223-226 (2002) [C1]
|
|
|
2002 |
Frost MJ, Ferrao PT, Hughes T, Ashman LK, 'Juxtamembrane Mutant V560GKit Is more Sensitive to Imatinib (ST1571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit is Resistant', Molecular Cancer Therapeutics, 1 1115-1124 (2002) [C1]
|
|
Nova |
2002 |
Fletcher J, Fletcher C, Rubin B, Ashman LK, Corless C, Heinrich M, 'KIT Gene Mutations in Gastrointestinal Stromal Tumors - More Complex than Previously Recognized?', American Journal of Pathology, 161, No 2 737-738 (2002) [C3]
|
|
|
2001 |
Geary SM, Cambaren AC, Fitter S, Ashman LK, 'Differential tissue expression of epitopes of the tetraspanin CD151 recognised by monoclonal antibodies', Tissue Antigens, 58 142-153 (2001) [C1]
|
|
|
2001 |
Chian RJ, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, et al., 'Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant', BLOOD, 98 1365-1373 (2001)
|
|
|
2001 |
Chian R, Young SM, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, et al., 'PI3-kinase mediates transformation of hematopoietic cells by the V816 c-Kit mutant', Blood, 98 1365-1373 (2001) [C1] |
|
|
2001 |
Berditchevski F, Gilbert E, Griffiths MR, Fitter S, Ashman L, Jenner SJ, 'Analysis of the CD151 center dot alpha(3)beta(1) integrin and CD151 center dot tetraspanin interactions by mutagenesis.', JOURNAL OF BIOLOGICAL CHEMISTRY, 276 41165-41174 (2001)
|
|
|
2001 |
Berditchevksi F, Gilbert E, Griffiths MR, Fitter S, Ashman L, Jenner SJ, 'Analysis of the CD151-a3b1 integrin and CD151-tetraspanin interactions by mutagenesis 41165-41174 (2001) [C1]
|
|
|
2001 |
Ferrao P, Sincock P, Cole S, Ashman L, 'Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia', LEUKEMIA RESEARCH, 25 395-405 (2001)
|
|
|
2001 |
Ferrao P, Sincock P, Cole S, Ashman L, 'Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia (vol 25, pg 395, 2001)', LEUKEMIA RESEARCH, 25 827-827 (2001)
|
|
|
2001 |
Ferrao PT, Frost MJ, Coles CJ, Domaschenz RM, Hughes TP, Ashman LK, 'Activated mutant D816VKit confers resistance to chemotherapeutic drugs, irradiation and STI 571.', CLINICAL CANCER RESEARCH, 7 3742S-3742S (2001) |
|
|
2000 |
Linnekin D, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, et al., 'PI3 kinase mediates transformation of hematopoietic cells by THF V816 c-Kit mutant.', BLOOD, 96 498A-498A (2000) |
|
|
2000 |
Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, et al., 'P13 kinase mediates transformation of hematopoietic cells by the V816 c-Kit mutant', EXPERIMENTAL HEMATOLOGY, 28 1491-1491 (2000)
|
|
|
2000 |
Ashman LK, Ferrao P, Cole SR, Cambareri AC, 'Effects of mutant c-Kit in early myeloid cells (vol 34, pg 451, 1997)', LEUKEMIA & LYMPHOMA, 37 233-243 (2000)
|
|
|
2000 |
Ashman LK, Ferrao P, Cole SR, Cambareri AC, 'Erratum: Effects of mutant c-kit in early myeloid cells (Leukemia and Lymphoma, 34, 5-6 (451-461))', Leukemia and Lymphoma, 37 233-243 (2000)
Activating mutations in c-Kit, the receptor for Stem Cell Factor (SCF), have been identified in dysplasias and leukaemias of the mast cell lineage and have been shown to contribut... [more]
Activating mutations in c-Kit, the receptor for Stem Cell Factor (SCF), have been identified in dysplasias and leukaemias of the mast cell lineage and have been shown to contribute to transformation in model systems. Early myeloid cells also normally express c-Kit and their survival, proliferation and differentiation is promoted by SCE It might therefore be expected that c-Kit mutations could also be involved in some acute and/or chronic myeloid leukaemias. We have found that mutant c-Kit (and normal c-Kit in the presence of SCF) provides a strong differentiation stimulus in normal and immortalised murine early myeloid cells. Since maturation of haemopoietic cells, with the exception of mast cells, results in down-regulation of c-Kit expression, the transforming effects of mutant receptor may be self-limiting in most lineages. This is consistent with the observation that multipotential progenitor cells from some patients with systemic mastocytosis express mutant c-Kit. However, c-Kit mutations have been observed in a few cases of myelodysplastic syndromes or AML without mast cell features. Oncogenesis involves multiple genetic changes and the phenotype of malignant haemopoietic cells expressing mutant c-Kit may be influenced by co-oncogenic events. For example mutations blocking the differentiative effect of mutant c-Kit might result in AML rather than mastocytosis. Thus the extent to which c-Kit mutations contribute to malignancies of early myeloid phenotype remains unknown, and resolution of this issue is complicated by the heterogeneity of this family of diseases.
|
|
|
1999 |
Brach MA, Buhring HJ, Gruss HJ, Ashman LK, Ludwig D, Mertelsmann RH, Herrmann F, 'Erratum: Functional expression of c-kit by acute myelogenous leukemia blasts is enhanced by tumor necrosis factor-a through posttranscriptional mRNA stabilization by a labile protein (Blood (1992) 80 (1224))', Blood, 93 3573 (1999) |
|
|
1999 |
Heberlein C, Friel J, Laker C, von Laer D, Bergholz U, Bogel M, et al., 'Downregulation of c-kit (stem cell factor receptor) in transformed hematopoietic precursor cells by stroma cells', BLOOD, 93 554-563 (1999)
|
|
|
1999 |
Brach MA, Buhring HJ, Gruss HJ, Ashman LK, Ludwig WD, Mertelsmann RH, Herrmann F, 'Functional expression of c-kit by acute myelogenous leukemia blasts is enhanced by tumor necrosis factor-alpha through posttranscriptional mRNA stabilization by a labile protein (Retraction of vol 80, pg 1224, 1992)', BLOOD, 93 3573-3573 (1999) |
|
|
1999 |
Brach MA, Herrmann F, Kufe DW, 'Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells (Retraction of vol 79, pg 728, 1992)', BLOOD, 93 3573-3573 (1999) |
|
|
1999 |
Gibson MA, Leavesley DI, Ashman LK, 'Microfibril-associated glycoprotein-2 specifically interacts with a range of bovine and human cell types via alpha(v)beta(3) integrin', JOURNAL OF BIOLOGICAL CHEMISTRY, 274 13060-13065 (1999)
|
|
|
1999 |
Sincock PM, Fitter S, Parton RG, Berndt MC, Gamble JR, Ashman LK, 'PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function', JOURNAL OF CELL SCIENCE, 112 833-844 (1999)
|
|
|
1999 |
Fitter S, Sincock PM, Jolliffe CN, Ashman LK, 'Transmembrane 4 superfamily protein CD151 (PETA-3) associates with beta(1) and alpha(IIb)beta(3) integrins in haemopoietic cell lines and modulates cell-cell adhesion', BIOCHEMICAL JOURNAL, 338 61-70 (1999)
|
|
|
1999 |
Linnekin D, Ashman L, Ferrao P, Chian R, Keller J, 'Signaling mechanisms of an oncogenic form of c-Kit in hematopoietic cells', EXPERIMENTAL HEMATOLOGY, 27 56-56 (1999) |
|
|
1999 |
Caruana G, Cambareri AC, Ashman LK, 'Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts', ONCOGENE, 18 5573-5581 (1999)
|
|
|
1999 |
Ashman LK, Ferrao P, Cole SR, Cambareri AC, 'Effects of mutant c-Kit in early myeloid cells', LEUKEMIA & LYMPHOMA, 34 451-461 (1999)
|
|
|
1999 |
Ashman LK, 'The biology of stem cell factor and its receptor C-kit', INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 31 1037-1051 (1999)
|
|
|
1998 |
Okayama Y, Kobayashi H, Ashman LK, Dobashi K, Nakazawa T, Holgate ST, et al., 'Human lung mast cells are enriched in the capacity to produce granulocyte-macrophage colony-stimulating factor in response to IgE-dependent stimulation', EUROPEAN JOURNAL OF IMMUNOLOGY, 28 708-715 (1998)
|
|
|
1998 |
Yanez-Mo M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa MA, et al., 'Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha 3 beta 1 integrin localized at endothelial lateral junctions', JOURNAL OF CELL BIOLOGY, 141 791-804 (1998)
|
|
|
1998 |
Fitter S, Seldin MF, Ashman LK, 'Characterisation of the mouse homologue of CD151 (PETA-3/SFA-1); genomic structure, chromosomal localisation and identification of 2 novel splice forms', BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1398 75-85 (1998)
|
|
|
1998 |
Afonja O, Amorosi E, Ashman L, Takeshita K, 'Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis', ANNALS OF HEMATOLOGY, 77 183-186 (1998)
|
|
|
1998 |
Caruana G, Cambareri AC, Gonda TJ, Ashman LK, 'Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement', ONCOGENE, 16 179-190 (1998)
|
|
|
1998 |
Okayama Y, Kobayashi H, Ashman LK, Dobashi K, Nakazawa T, Holgate ST, et al., 'Human lung mast cells are enriched in the capacity to produce granulocyte-macrophage colony-stimulating factor in response to IgE-dependent stimulation', European Journal of Immunology, 28 708-715 (1998)
By using reverse transcription-PCR, in situ hybridization, enzyme-linked immunosorbent assay and immunocytochemistry, we have studied the production of granulocyte-macrophage colo... [more]
By using reverse transcription-PCR, in situ hybridization, enzyme-linked immunosorbent assay and immunocytochemistry, we have studied the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) in human lung mast cells induced by cross-linkage of high-affinity Fce receptors (FceRI). We have also confirmed the bioactivity of GM-CSF released from lung mast cells by investigating the effect of the supernatant from lung mast cells activated with anti-IgE on the release of eosinophil cationic protein (ECP) from eosinophils. Mast cells were purified using affinity magnetic selection with monoclonal antibody (mAb) YB5.B8 (93-99% pure). Purified mast cells were precultured with IgE for 16 h before challenge with 1 µg/ml anti-IgE with or without stem cell factor (SCF). Eosinophils were purified by immunomagnetic negative selection (> 98% pure). The activation of mast cells via FceRI enhanced the intensity of the GM-CSF signal within 2 h and the cells produced GM-CSF protein 4 h after the activation. In the absence of recombinant human (rh) SCF, anti-IgE induced a median GM-CSF response of 202 (< 15 ~ 681) pg/106 mast cells/24 h, whereas in the presence of rhSCF the median IgE-dependent GM-CSF release was 356 (152 ~ 1216) pg/106 mast cells/24 h. This difference was statistically significant (p = 0.0029, n = 12). In contrast, mast cells produced only a small amount of GM-CSF in the absence of anti-IgE. The mast cell supernatant induced ECP release from eosinophils and the release was significantly inhibited by blocking mAb against GM-CSF. These findings indicate that human mast cells are an important cellular source of GM-CSF and as such may contribute to chronic eosinophil-mediated inflammation.
|
|
|
1997 |
Ferrao P, Gonda TJ, Ashman LK, 'Expression of constitutively activated human c-Kit in myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity', BLOOD, 90 4539-4552 (1997)
|
|
|
1997 |
Sincock PM, Mayrhofer G, Ashman LK, 'Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: Comparison with CD9, CD63, and alpha 5 beta 1 integrin', JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 45 515-525 (1997)
|
|
|
1997 |
Atkins GJ, Qiao M, Coombe DR, Gowans EJ, Ashman LK, 'Hepatitis B virus binding to leucocyte plasma membranes utilizes a different region of the preS1 domain to the hepatocyte receptor binding site and does not require receptors for opsonins', IMMUNOLOGY AND CELL BIOLOGY, 75 259-266 (1997)
|
|
|
1997 |
Sincock PM, Ashman LK, 'Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia', LEUKEMIA, 11 1850-1857 (1997)
|
|
|
1997 |
Zannettino ACW, Aylett GW, Leavesley DI, Pietsch T, Chang DG, Simmons PJ, Ashman LK, 'Specificity and functional effects of antibodies to human stem cell factor', GROWTH FACTORS, 14 67-79 (1997)
|
|
|
1996 |
Kurosawa K, Miyazawa K, Gotoh A, Katagiri T, Nishimaki J, Ashman LK, Toyama K, 'Immobilized anti-KIT monoclonal antibody induces ligand-independent dimerization and activation of steel factor receptor: Biologic similarity with membrane-bound form of steel factor rather than its soluble form', BLOOD, 87 2235-2243 (1996)
|
|
|
1996 |
Geary SM, Ashman LK, 'HL-60 myeloid leukaemia cells acquire immunostimulatory capability upon treatment with retinoic acid: Analysis of the responding population and mechanism of cytotoxic lymphocyte activation', IMMUNOLOGY, 88 428-440 (1996)
|
|
|
1996 |
Zannettino ACW, Rayner JR, Ashman LK, Gonda TJ, Simmons PJ, 'A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning', JOURNAL OF IMMUNOLOGY, 156 611-620 (1996)
|
|
|
1996 |
Shimizu YJ, Ashman LK, Du ZM, Schwartz LB, 'Internalization of Kit together with stem cell factor on human fetal liver-derived mast cells - New protein and RNA synthesis is required for reappearance of Kit', JOURNAL OF IMMUNOLOGY, 156 3443-3449 (1996)
|
|
|
1996 |
Baghestanian M, Agis H, Bevec D, Bankl HC, Hofbauer R, Kress HG, et al., 'Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells', EXPERIMENTAL HEMATOLOGY, 24 1377-1386 (1996)
|
|
|
1996 |
Cole SR, Aylett GW, Casey G, Harvey NL, Cambareri AC, Ashman LK, 'Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia', LEUKEMIA, 10 288-296 (1996)
|
|
|
1996 |
Gattei V, Aldinucci D, Quinn JMW, Degan M, Cozzi M, Perin V, et al., 'Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor', CELL GROWTH & DIFFERENTIATION, 7 753-763 (1996)
|
|
|
1995 |
KEES UR, ASHMAN LK, 'SYNERGISTIC ACTION OF INTERLEUKIN-2 AND STEEL FACTOR (SLF) ON A HUMAN T-LYMPHOBLASTOID CELL-LINE', LEUKEMIA, 9 1046-1050 (1995)
|
|
|
1995 |
SHIMIZU Y, ASHMAN L, SCHWARTZ LB, 'REGULATION OF KIT DURING STEM-CELL FACTOR (SCF)-DEPENDENT DEVELOPMENT OF FETAL LIVER-DERIVED HUMAN MAST-CELLS', FASEB JOURNAL, 9 A200-A200 (1995) |
|
|
1995 |
FERRAO P, MACMILLAN EM, ASHMAN LK, GONDA TJ, 'ENFORCED EXPRESSION OF FULL-LENGTH C-MYB LEADS TO DENSITY-DEPENDENT TRANSFORMATION OF MURINE HEMATOPOIETIC-CELLS', ONCOGENE, 11 1631-1638 (1995)
|
|
|
1995 |
SHIMIZU Y, IRANI AMA, BROWN EJ, ASHMAN LK, SCHWARTZ LB, 'HUMAN MAST-CELLS DERIVED FROM FETAL LIVER-CELLS CULTURED WITH STEM-CELL FACTOR EXPRESS A FUNCTIONAL CD51/CD61 (ALPHA-V-BETA-3) INTEGRIN', BLOOD, 86 930-939 (1995)
|
|
|
1995 |
FITTER S, TETAZ TJ, BERNDT MC, ASHMAN LK, 'MOLECULAR-CLONING OF CDNA-ENCODING A NOVEL PLATELET-ENDOTHELIAL CELL TETRA-SPAN ANTIGEN, PETA-3', BLOOD, 86 1348-1355 (1995)
|
|
|
1995 |
Gattei V, Aldinucci D, Quinn JMW, Degan M, Cozzi M, Perin V, et al., 'Human primary osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor (mb-SCF)', BLOOD, 86 79-79 (1995) |
|
|
1995 |
Ashman LK, Sincock PM, Cole SR, 'Functional drug efflux P-glycoprotein and c-Kit expression in acute myeloid leukemia.', BLOOD, 86 2048-2048 (1995) |
|
|
1995 |
Zannettino ACW, Buhring HJ, Niutta S, Ashman LK, Kanz L, Simmons PJ, 'Identification and functional cloning of MGC-24, a mucin-like molecule expressed by haemopoietic progenitors and bone marrow stromal cells: A negative regulator of haemopoiesis', BLOOD, 86 2350-2350 (1995)
|
|
|
1995 |
ROBERTS JJ, RODGERS SE, DRURY J, ASHMAN LK, LLOYD JV, 'PLATELET ACTIVATION-INDUCED BY A MURINE MONOCLONAL-ANTIBODY DIRECTED AGAINST A NOVEL TETRA-SPAN ANTIGEN', BRITISH JOURNAL OF HAEMATOLOGY, 89 853-860 (1995) [C1]
|
|
|
1995 |
IRANI AA, NILSSON G, ASHMAN LK, SCHWARTZ LB, 'DEXAMETHASONE INHIBITS THE DEVELOPMENT OF MAST-CELLS FROM DISPERSED HUMAN FETAL LIVER-CELLS CULTURED IN THE PRESENCE OF RECOMBINANT HUMAN STEM-CELL FACTOR', IMMUNOLOGY, 84 72-78 (1995)
|
|
|
1995 |
ASHMAN LK, AYLETT GW, CAMBARERI AC, LEVESQUE JP, SIMMONS PJ, 'STEEL FACTOR AND ITS RECEPTOR C-KIT MEDIATE CELL-CELL INTERACTIONS', JOURNAL OF INVESTIGATIVE DERMATOLOGY, 105 2-2 (1995) |
|
|
1994 |
NILSSON G, MIETTINEN U, ISHIZAKA T, ASHMAN LK, IRANI AM, SCHWARTZ LB, 'INTERLEUKIN-4 INHIBITS THE EXPRESSION OF KIT AND TRYPTASE DURING STEM-CELL FACTOR-DEPENDENT DEVELOPMENT OF HUMAN MAST-CELLS FROM FETAL LIVER-CELLS', BLOOD, 84 1519-1527 (1994)
|
|
|
1994 |
TO LB, HAYLOCK DN, DOWSE T, SIMMONS PJ, TRIMBOLI S, ASHMAN LK, JUTTNER CA, 'A COMPARATIVE-STUDY OF THE PHENOTYPE AND PROLIFERATIVE CAPACITY OF PERIPHERAL-BLOOD (PB) CD34(+) CELLS MOBILIZED BY 4 DIFFERENT PROTOCOLS AND THOSE OF STEADY-PHASE PB AND BONE-MARROW CD34(+) CELLS', BLOOD, 84 2930-2939 (1994)
|
|
|
1994 |
KUROSAWA K, MIYAZAWA K, GOTOH A, NISHIMAKI J, ASHMAN LK, TOYAMA K, 'IMMOBILIZED YB5.B8 MONOCLONAL-ANTIBODY INDUCES LIGAND-INDEPENDENT DIMERIZATION AND ACTIVATION OF C-KIT ENCODED PROTEIN - BIOLOGICAL SIMILARITY WITH MEMBRANE-BOUND FORM OF STEEL FACTOR RATHER THAN ITS SOLUBLE FORM', BLOOD, 84 A123-A123 (1994) |
|
|
1994 |
ASHMAN LK, FITTER S, TETAZ T, BERNDT MC, 'MOLECULAR-CLONING OF CDNA-ENCODING A NOVEL PLATELET ENDOTHELIAL-CELL TETRASPAN ANTIGEN', BLOOD, 84 A243-A243 (1994) |
|
|
1994 |
ASHMAN LK, BUHRING HJ, AYLETT GW, BROUDY VC, MULLER C, 'EPITOPE MAPPING AND FUNCTIONAL-STUDIES WITH 3 MONOCLONAL-ANTIBODIES TO THE C-KIT RECEPTOR TYROSINE KINASE, YB5.B8, 17F11, AND SR-1', JOURNAL OF CELLULAR PHYSIOLOGY, 158 545-554 (1994)
|
|
|
1994 |
OKAYAMA Y, HUNT TC, KASSEL O, ASHMAN LK, CHURCH MK, 'ASSESSMENT OF THE ANTI-C-KIT MONOCLONAL-ANTIBODY YB5.B8 IN AFFINITY MAGNETIC ENRICHMENT OF HUMAN LUNG MAST-CELLS', JOURNAL OF IMMUNOLOGICAL METHODS, 169 153-161 (1994)
|
|
|
1994 |
GRABBE J, WELKER P, MOLLER A, DIPPEL E, ASHMAN LK, CZARNETZKI BM, 'COMPARATIVE CYTOKINE RELEASE FROM HUMAN MONOCYTES, MONOCYTE-DERIVED IMMATURE MAST-CELLS, AND A HUMAN MAST-CELL LINE (HMC-1)', JOURNAL OF INVESTIGATIVE DERMATOLOGY, 103 504-508 (1994)
|
|
|
1994 |
SIMMONS PJ, AYLETT GW, NIUTTA S, TO LB, JUTTNER CA, ASHMAN LK, 'C-KIT IS EXPRESSED BY PRIMITIVE HUMAN HEMATOPOIETIC-CELLS THAT GIVE RISE TO COLONY-FORMING CELLS IN STROMA-DEPENDENT CYTOKINE-SUPPLEMENTED CULTURE', EXPERIMENTAL HEMATOLOGY, 22 157-165 (1994)
|
|
|
1994 |
OKAYAMA Y, HUNT TC, KASSEL O, ASHMAN L, CHURCH MK, 'ASSESSMENT OF THE ANTI-C-KIT MONOCLONAL-ANTIBODY - YB5,B8 IN MAGNETIC AFFINITY ENRICHMENT OF HUMAN MAST-CELLS PREPARATIONS', CLINICAL AND EXPERIMENTAL ALLERGY, 24 179-179 (1994) |
|
|
1994 |
SIMMONS PJ, LEAVESLEY DI, LEVESQUE JP, SWART BW, HAYLOCK DN, TO LB, et al., 'THE MOBILIZATION OF PRIMITIVE HEMATOPOIETIC PROGENITORS INTO THE PERIPHERAL-BLOOD', STEM CELLS, 12 187-202 (1994)
|
|
|
1993 |
TO LB, HAYLOCK DN, DOWSE T, SIMMONS PJ, ASHMAN LK, JUTTNER CA, 'PHENOTYPE AND PROLIFERATIVE CAPACITY OF PERIPHERAL-BLOOD CD34+ CELLS MOBILIZED BY 4 DIFFERENT PROTOCOLS', BLOOD, 82 A493-A493 (1993)
|
|
|
1993 |
LLOYD JV, ROBERTS JJ, RODGERS SE, ASHMAN LK, 'PLATELET ACTIVATION BY THE MURINE MONOCLONAL ANTIBODY-14A2.H1', BLOOD, 82 A609-A609 (1993) |
|
|
1993 |
NILSSON G, FORSBERG K, BODGER MP, ASHMAN LK, ZSEBO KM, ISHIZAKA T, et al., 'PHENOTYPIC CHARACTERIZATION OF STEM-CELL FACTOR-DEPENDENT HUMAN FETAL LIVER-DERIVED MAST-CELLS', IMMUNOLOGY, 79 325-330 (1993)
|
|
|
1993 |
TOHDA S, YANG GS, ASHMAN LK, MCCULLOCH EA, MINDEN MD, 'RELATIONSHIP BETWEEN C-KIT EXPRESSION AND PROLIFERATION IN ACUTE MYELOBLASTIC-LEUKEMIA CELL-LINES', JOURNAL OF CELLULAR PHYSIOLOGY, 154 410-418 (1993)
|
|
|
1993 |
FURITSU T, TSUJIMURA T, TONO T, IKEDA H, KITAYAMA H, KOSHIMIZU U, et al., 'IDENTIFICATION OF MUTATIONS IN THE CODING SEQUENCE OF THE PROTOONCOGENE C-KIT IN A HUMAN MAST-CELL LEUKEMIA-CELL LINE CAUSING LIGAND-INDEPENDENT ACTIVATION OF C-KIT PRODUCT', JOURNAL OF CLINICAL INVESTIGATION, 92 1736-1744 (1993)
|
|
|
1993 |
MATOS ME, SCHNIER GS, BEECHER MS, ASHMAN LK, WILLIAMS DE, CALIGIURI MA, 'EXPRESSION OF A FUNCTIONAL C-KIT RECEPTOR ON A SUBSET OF NATURAL-KILLER-CELLS', JOURNAL OF EXPERIMENTAL MEDICINE, 178 1079-1084 (1993)
|
|
|
1993 |
ASANO Y, BRACH MA, AHLERS A, DEVOS S, BUTTERFIELD JH, ASHMAN LK, et al., 'PHORBOL ESTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE DOWN-REGULATES EXPRESSION OF THE C-KIT PROTOONCOGENE PRODUCT', JOURNAL OF IMMUNOLOGY, 151 2345-2354 (1993)
|
|
|
1993 |
MAZE R, HORIE M, HENDRIE P, VADHANRAJ S, TRICOT G, GORDON M, et al., 'DIFFERENTIAL RESPONSES OF MYELOID PROGENITOR CELLS FROM PATIENTS WITH MYELOID-LEUKEMIA AND MYELODYSPLASIA TO THE COSTIMULATING EFFECTS OF STEEL FACTOR IN-VITRO', EXPERIMENTAL HEMATOLOGY, 21 545-551 (1993)
|
|
|
1993 |
CARUANA G, ASHMAN LK, FUJITA J, GONDA TJ, 'RESPONSES OF THE MURINE MYELOID CELL-LINE FDC-P1 TO SOLUBLE AND MEMBRANE-BOUND FORMS OF STEEL FACTOR (SLF)', EXPERIMENTAL HEMATOLOGY, 21 761-768 (1993)
|
|
|
1993 |
ATKINS GJ, GOWANS EJ, ASHMAN LK, 'HEPATITIS-B VIRUS RECEPTORS ON HEMATOPOIETIC-CELLS', JOURNAL OF LEUKOCYTE BIOLOGY, 46-46 (1993) |
|
|
1993 |
GEARY SM, ASHMAN LK, 'IMMUNOSTIMULATORY NATURE OF A HUMAN LEUKEMIC-CELL LINE, HL-60, AFTER TREATMENT WITH RETINOIC ACID', JOURNAL OF LEUKOCYTE BIOLOGY, 89-89 (1993) |
|
|
1993 |
ZANNETTINO ACW, RAYNER JR, ASHMAN LK, GONDA TJ, SIMMONS PJ, 'USE OF A RETROVIRAL CDNA EXPRESSION LIBRARY TO CLONE GENES ENCODING NOVEL HUMAN STROMAL CELL ANTIGENS', JOURNAL OF LEUKOCYTE BIOLOGY, 103-103 (1993) |
|
|
1993 |
FITTER S, BERNDT MC, ZANNETTINO ACW, ASHMAN LK, 'MOLECULAR-CLONING OF CDNA-ENCODING A NOVEL HUMAN PLATELET MEGAKARYOCYTE SURFACE-ANTIGEN', JOURNAL OF LEUKOCYTE BIOLOGY, 103-103 (1993) |
|
|
1993 |
TOHDA S, ASHMAN LK, MINDEN MD, 'THE ROLE OF STROMA CELLS ON THE PROLIFERATION AND C-KIT EXPRESSION OF ACUTE MYELOBLASTIC-LEUKEMIA CELLS', INTERNATIONAL JOURNAL OF ONCOLOGY, 3 1141-1147 (1993) |
|
|
1992 |
CICUTTINI FM, MARTIN M, SALVARIS E, ASHMAN L, BEGLEY CG, NOVOTNY J, et al., 'SUPPORT OF HUMAN CORD BLOOD PROGENITOR CELLS ON HUMAN STROMAL CELL-LINES TRANSFORMED BY SV(40) LARGE T-ANTIGEN UNDER THE INFLUENCE OF AN INDUCIBLE (METALLOTHIONEIN) PROMOTER', BLOOD, 80 102-112 (1992)
|
|
|
1992 |
BRACH MA, BUHRING HJ, GRUSS HJ, ASHMAN LK, LUDWIG WD, MERTELSMANN RH, HERRMANN F, 'FUNCTIONAL EXPRESSION OF C-KIT BY ACUTE MYELOGENOUS LEUKEMIA BLASTS IS ENHANCED BY TUMOR-NECROSIS-FACTOR-ALPHA THROUGH POSTTRANSCRIPTIONAL MESSENGER-RNA STABILIZATION BY A LABILE PROTEIN (RETRACTED ARTICLE. SEE VOL 93, PG. 3573, 1999)', BLOOD, 80 1224-1230 (1992)
|
|
|
1992 |
IRANI AMA, NILSSON G, MIETTINEN U, CRAIG SS, ASHMAN LK, ISHIZAKA T, et al., 'RECOMBINANT HUMAN STEM-CELL FACTOR STIMULATES DIFFERENTIATION OF MAST-CELLS FROM DISPERSED HUMAN FETAL LIVER-CELLS', BLOOD, 80 3009-3021 (1992)
|
|
|
1992 |
JACOBSON MR, BENTLEY AM, CUMBERWORTH V, SCHWARTZ LB, IRANI AM, ASHMAN LK, et al., 'IMMUNOHISTOLOGY OF THE NASAL-MUCOSA IN SEASONAL ALLERGIC RHINITIS - INCREASES IN ACTIVATED EOSINOPHILS AND EPITHELIAL MAST-CELLS', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 89 216-216 (1992)
|
|
|
1992 |
HUNT TC, HEUSSER C, MUELLER R, BULLOCK G, OKAYAMA Y, ASHMAN LK, CHURCH MK, 'HUMAN LUNG MAST-CELLS PRODUCE INTERLEUKIN-4', JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 89 245-245 (1992)
|
|
|
1992 |
MAZE R, HORIE M, HENDRIE PC, VADHANRAJ S, TRICOT G, ASHMAN LK, BROXMEYER HE, 'HETEROGENEOUS RESPONSIVENESS INVITRO OF MYELOID PROGENITOR CELLS FROM PATIENTS WITH MYELOID-LEUKEMIA TO THE CO-STIMULATING EFFECTS OF STEEL FACTOR', EXPERIMENTAL HEMATOLOGY, 20 761-761 (1992) |
|
|
1992 |
SIMMONS PJ, NIUTTA S, ASHMAN LK, BERNDT MC, JUTTNER CA, 'PRIMITIVE HUMAN BONE-MARROW PROGENITORS EXPRESS L-SELECTIN AND PECAM-1(CD31)', EXPERIMENTAL HEMATOLOGY, 20 829-829 (1992)
|
|
|
1991 |
ASHMAN LK, AYLETT GW, CAMBARERI AC, COLE SR, 'DIFFERENT EPITOPES OF THE CD31 ANTIGEN IDENTIFIED BY MONOCLONAL-ANTIBODIES - CELL TYPE-SPECIFIC PATTERNS OF EXPRESSION', TISSUE ANTIGENS, 38 199-207 (1991)
|
|
|
1991 |
ASHMAN LK, AYLETT GW, 'EXPRESSION OF CD31-EPITOPES ON HUMAN-LYMPHOCYTES - CD31-MONOCLONAL ANTIBODIES DIFFERENTIATE BETWEEN NAIVE (CD45RA+) AND MEMORY (CD45RA-) CD4-POSITIVE T-CELLS', TISSUE ANTIGENS, 38 208-212 (1991)
|
|
|
1991 |
LERNER NB, NOCKA KH, COLE SR, QIU FH, STRIFE A, ASHMAN LK, BESMER P, 'MONOCLONAL ANTIBODY-YB5.B8 IDENTIFIES THE HUMAN C-KIT PROTEIN PRODUCT', BLOOD, 77 1876-1883 (1991)
|
|
|
1991 |
ASHMAN LK, CAMBARERI AC, TO LB, LEVINSKY RJ, JUTTNER CA, 'EXPRESSION OF THE YB5.B8 ANTIGEN (C-KIT PROTOONCOGENE PRODUCT) IN NORMAL HUMAN BONE-MARROW', BLOOD, 78 30-37 (1991)
|
|
|
1991 |
ASHMAN LK, AYLETT GW, MEHRABANI PA, BENDALL LJ, NIUTTA S, CAMBARERI AC, et al., 'THE MURINE MONOCLONAL-ANTIBODY, 14A2.H1, IDENTIFIES A NOVEL PLATELET SURFACE-ANTIGEN', BRITISH JOURNAL OF HAEMATOLOGY, 79 263-270 (1991)
|
|
|
1991 |
SILLABER C, STROBL H, BEVEC D, ASHMAN LK, BUTTERFIELD JH, LECHNER K, et al., 'IL-4 REGULATES C-KIT PROTOONCOGENE PRODUCT EXPRESSION IN HUMAN MAST AND MYELOID PROGENITOR CELLS', JOURNAL OF IMMUNOLOGY, 147 4224-4228 (1991)
|
|
|
1991 |
MIYAZAWA K, HENDRIE PC, MANTEL C, WOOD K, ASHMAN LK, BROXMEYER HE, 'COMPARATIVE-ANALYSIS OF SIGNALING PATHWAYS BETWEEN MAST-CELL GROWTH-FACTOR (C-KIT LIGAND) AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN A HUMAN FACTOR-DEPENDENT MYELOID CELL-LINE INVOLVES PHOSPHORYLATION OF RAF-1, GTPASE-ACTIVATING PROTEIN AND MITOGEN-ACTIVATED PROTEIN-KINASE', EXPERIMENTAL HEMATOLOGY, 19 1110-1123 (1991)
|
|
|
1990 |
ASHMAN LK, CAMBARERI AC, EGLINTON JM, 'A MONOCLONAL-ANTIBODY THAT INHIBITS THE ACTION OF GM-CSF ON NORMAL BUT NOT LEUKEMIC PROGENITORS', LEUKEMIA RESEARCH, 14 637-644 (1990)
|
|
|
1989 |
VALENT P, ASHMAN LK, HINTERBERGER W, ECKERSBERGER F, MAJDIC O, LECHNER K, BETTELHEIM P, 'MAST-CELL TYPING - DEMONSTRATION OF A DISTINCT HEMATOPOIETIC-CELL TYPE AND EVIDENCE FOR IMMUNOPHENOTYPIC RELATIONSHIP TO MONONUCLEAR PHAGOCYTES', BLOOD, 73 1778-1785 (1989)
|
|
|
1989 |
COLE SR, KRIEK GW, HOPE RM, ASHMAN LK, 'TRANSFECTION OF GENES FOR HUMAN CELL-SURFACE ANTIGENS IDENTIFIED BY MONOCLONAL-ANTIBODIES', IMMUNOLOGY AND CELL BIOLOGY, 67 377-384 (1989)
|
|
|
1988 |
LYONS AB, COOPER SJ, COLE SR, ASHMAN LK, 'HUMAN MYELOID DIFFERENTIATION ANTIGENS IDENTIFIED BY MONOCLONAL-ANTIBODIES TO THE MYELOMONOCYTIC LEUKEMIA-CELL LINE RC-2A', PATHOLOGY, 20 137-146 (1988)
|
|
|
1988 |
LYONS AB, ASHMAN LK, 'THE EFFECT OF RECOMBINANT CYTOKINES ON THE PROLIFERATIVE POTENTIAL AND PHENOTYPE OF CELLS OF THE HUMAN MYELOMONOCYTIC LEUKEMIA LINE, RC-2A', LEUKEMIA RESEARCH, 12 659-666 (1988)
|
|
|
1988 |
ASHMAN LK, ROBERTS MM, GADD SJ, COOPER SJ, JUTTNER CA, 'EXPRESSION OF A 150-KD CELL-SURFACE ANTIGEN IDENTIFIED BY MONOCLONAL-ANTIBODY YB5.B8 IS ASSOCIATED WITH POOR PROGNOSIS IN ACUTE NON-LYMPHOBLASTIC LEUKEMIA', LEUKEMIA RESEARCH, 12 923-928 (1988)
|
|
|
1988 |
CAMBARERI AC, ASHMAN LK, COLE SR, LYONS AB, 'A MONOCLONAL-ANTIBODY TO A HUMAN MAST-CELL MYELOID LEUKEMIA-SPECIFIC ANTIGEN BINDS TO NORMAL HEMATOPOIETIC PROGENITOR CELLS AND INHIBITS COLONY FORMATION INVITRO', LEUKEMIA RESEARCH, 12 929-+ (1988)
|
|
|
1987 |
VALENT P, STAIN C, ASHMAN LK, BRANTSCHEN S, STADLER BM, HINTERBERGER W, et al., 'THE PHENOTYPE OF HUMAN CONNECTIVE-TISSUE TYPE (CTMC) AND MUCOSAL MAST-CELLS (MMC)', BLUT, 55 360-360 (1987) |
|
|
1987 |
WHITE DL, ASHMAN LK, DART GW, ZOLA H, TOOGOOD IRG, KIMBER RJ, 'THE EXPRESSION OF MATURE MYELOID CELL-DIFFERENTIATION MARKERS IN ACUTE-LEUKEMIA', PATHOLOGY, 19 137-142 (1987)
|
|
|
1987 |
ASHMAN L, ROBERTS M, GADD S, COOPER S, JUTTNER C, 'A SUBGROUP OF ANLL WITH POOR RESPONSE TO STANDARD CHEMOTHERAPY IDENTIFIED BY A MONOCLONAL-ANTIBODY', MEDICAL AND PEDIATRIC ONCOLOGY, 15 152-152 (1987) |
|
|
1987 |
ASHMAN LK, WHITE D, ZOLA H, DART GW, 'EXPRESSION OF THE NON-T ALL-ASSOCIATED P24 ANTIGEN ON LEUKEMIC BLASTS FROM PATIENTS WITH ANLL', LEUKEMIA RESEARCH, 11 97-& (1987)
|
|
|
1987 |
LYONS AB, ASHMAN LK, 'STUDIES ON THE DIFFERENTIATION OF THE HUMAN MYELOMONOCYTIC CELL-LINE RC-2A IN RESPONSE TO LYMPHOCYTE-DERIVED FACTORS', LEUKEMIA RESEARCH, 11 797-& (1987)
|
|
|
1987 |
COLE SR, ASHMAN LK, EY PL, 'BIOTINYLATION - AN ALTERNATIVE TO RADIOIODINATION FOR THE IDENTIFICATION OF CELL-SURFACE ANTIGENS IN IMMUNOPRECIPITATES', MOLECULAR IMMUNOLOGY, 24 699-705 (1987)
|
|
|
1987 |
ASHMAN LK, KRIEK GW, COOPER SJ, OKEEFE DE, 'REQUIREMENTS FOR THE STIMULATION OF ALLOGENEIC LYMPHOCYTES-T BY ACUTE NONLYMPHOBLASTIC LEUKEMIA-CELLS', CANCER IMMUNOLOGY IMMUNOTHERAPY, 25 250-256 (1987)
|
|
|
1987 |
ASHMAN LK, DREW PA, TOOGOOD IRG, JUTTNER CA, 'IMMUNOLOGICAL COMPETENCE OF PATIENTS IN REMISSION FROM ACUTE-LEUKEMIA - APPARENTLY NORMAL T-CELL FUNCTION BUT DEFECTIVE POKEWEED MITOGEN-DRIVEN IMMUNOGLOBULIN-SYNTHESIS', IMMUNOLOGY AND CELL BIOLOGY, 65 201-210 (1987)
|
|
|
1987 |
MAYRHOFER G, GADD SJ, SPARGO LDJ, ASHMAN LK, 'SPECIFICITY OF A MOUSE MONOCLONAL-ANTIBODY RAISED AGAINST ACUTE MYELOID-LEUKEMIA CELLS FOR MAST-CELLS IN HUMAN MUCOSAL AND CONNECTIVE TISSUES', IMMUNOLOGY AND CELL BIOLOGY, 65 241-250 (1987)
|
|
|
1987 |
ASHMAN LK, 'THE IMMUNOGENICITY OF TUMOR-CELLS', IMMUNOLOGY AND CELL BIOLOGY, 65 271-277 (1987)
|
|
|
1986 |
WHITE DL, ASHMAN LK, DART GW, ZOLA H, KIMBER RJ, 'THE SELECTION OF A PANEL OF LOCALLY PRODUCED MONOCLONAL-ANTIBODIES FOR THE CLASSIFICATION OF ACUTE LEUKEMIAS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 16 124-124 (1986) |
|
|
1986 |
EY PL, ASHMAN LK, 'THE USE OF ALKALINE PHOSPHATASE-CONJUGATED ANTIIMMUNOGLOBULIN WITH IMMUNOBLOTS FOR DETERMINING THE SPECIFICITY OF MONOCLONAL-ANTIBODIES TO PROTEIN MIXTURES', METHODS IN ENZYMOLOGY, 121 497-509 (1986)
|
|
|
1986 |
ASHMAN LK, OKEEFE DE, JUTTNER CA, TOOGOOD IRG, RICE MS, 'AUTOLOGOUS RESPONSES TO HUMAN-LEUKEMIC CELLS IN MIXED LEUKOCYTE-CULTURE', CANCER IMMUNOLOGY IMMUNOTHERAPY, 22 95-99 (1986)
|
|
|
1985 |
GADD SJ, BROGAN MP, ASHMAN LK, 'SPECIFICITY OF THE PASSIVE ANTIBODY-INDUCED SUPPRESSION OF THE HUMORAL IMMUNE-RESPONSE OF MICE TO SURFACE-ANTIGENS ON HUMAN-CELLS', IMMUNOLOGY, 54 223-231 (1985)
|
|
|
1985 |
GESCHE AH, ASHMAN LK, 'VARIATIONS IN ANTIGEN EXPRESSION DURING THE CELL-CYCLE OF A HUMAN B-LYMPHOBLASTOID CELL-LINE', LEUKEMIA RESEARCH, 9 147-& (1985)
|
|
|
1985 |
ASHMAN LK, GESCHE AH, 'SURFACE-ANTIGEN EXPRESSION BY A HUMAN B-LYMPHOBLASTOID CELL-LINE TREATED WITH DIFFERENTIATION INDUCERS, DIMETHYSULFOXIDE AND TETRADECANOYLPHORBOL ACETATE', LEUKEMIA RESEARCH, 9 157-& (1985)
|
|
|
1985 |
GADD SJ, ASHMAN LK, 'A MURINE MONOCLONAL-ANTIBODY SPECIFIC FOR A CELL-SURFACE ANTIGEN EXPRESSED BY A SUBGROUP OF HUMAN MYELOID LEUKEMIAS', LEUKEMIA RESEARCH, 9 1329-1336 (1985)
|
|
|
1985 |
LYONS AB, ASHMAN LK, 'THE ROSE-BENGAL ASSAY FOR MONOCLONAL-ANTIBODIES TO CELL-SURFACE ANTIGENS - COMPARISONS WITH COMMON HYBRIDOMA SCREENING METHODS', JOURNAL OF IMMUNOASSAY, 6 325-345 (1985)
|
|
|
1984 |
ASHMAN LK, 'PROLIFERATIVE RESPONSE OF NORMAL AND ACTIVATED HUMAN-LYMPHOCYTES TO TETRADECANOYL PHORBOL ACETATE', CELLULAR IMMUNOLOGY, 87 613-625 (1984)
|
|
|
1983 |
GADD SJ, ASHMAN LK, 'BINDING OF MOUSE MONOCLONAL-ANTIBODIES TO HUMAN-LEUKEMIC CELLS VIA THE FC RECEPTOR - A POSSIBLE SOURCE OF FALSE POSITIVE REACTIONS IN SPECIFICITY SCREENING', CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 54 811-818 (1983)
|
|
|
1983 |
ASHMAN LK, 'IMMUNE-RESPONSES TO HUMAN-LEUKEMIC CELLS-INVITRO', MEDICAL AND PEDIATRIC ONCOLOGY, 11 197-197 (1983) |
|
|
1983 |
Ashman LK, 'Stimulatory ability of human leukaemic cells in the allogeneic mixed leucocyte reaction', Australian Journal of Experimental Biology and Medical Science, 61 477-488 (1983)
|
|
|
1983 |
ASHMAN LK, 'STIMULATORY ABILITY OF HUMAN-LEUKEMIC CELLS IN THE ALLOGENEIC MIXED LEUKOCYTE REACTION', AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 61 477-488 (1983)
|
|
|
1982 |
OKEEFE D, ASHMAN L, 'PEANUT AGGLUTININ - A MARKER FOR NORMAL AND LEUKEMIC-CELLS OF THE MONOCYTE LINEAGE', CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 48 329-338 (1982)
|
|
|
1982 |
OKEEFE D, ASHMAN L, 'VARIATION IN ACCESSORY CELL REQUIREMENTS IN HUMAN MIXED LYMPHOCYTE-RESPONSE TO LEUKEMIC-CELL LINES', IMMUNOLOGY, 47 633-641 (1982)
|
|
|
1982 |
OCONNOR CG, ASHMAN LK, 'APPLICATION OF THE NITROCELLULOSE TRANSFER TECHNIQUE AND ALKALINE-PHOSPHATASE CONJUGATED ANTI-IMMUNOGLOBULIN FOR DETERMINATION OF THE SPECIFICITY OF MONOCLONAL-ANTIBODIES TO PROTEIN MIXTURES', JOURNAL OF IMMUNOLOGICAL METHODS, 54 267-271 (1982)
|
|
|
1982 |
ASHMAN LK, MURRAY AW, COOK MG, KOTLARSKI I, '2-STAGE SKIN CARCINOGENESIS IN SENSITIVE AND RESISTANT MOUSE STRAINS', CARCINOGENESIS, 3 99-102 (1982)
|
|
|
1980 |
VINGELIS V, ASHMAN LK, KOTLARSKI I, 'FACTORS AFFECTING THE ABILITY OF VARIOUS STRAINS OF ENTEROBACTERIACEAE TO INDUCE TUMOR RESISTANCE IN MICE', AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 58 123-131 (1980)
|
|
|
1980 |
ASHMAN LK, GOH DHB, KOTLARSKI I, 'INVOLVEMENT OF DONOR LYMPHORETICULAR CELLS IN THE REJECTION OF B-16 MELANOMA BY ALLOGENEIC MICE', AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 58 159-166 (1980)
|
|
|
1980 |
DEYOUNG NJ, ASHMAN LK, LUDBROOK J, MARSHALL VR, 'COMPARISON OF 3 BLOOD-TESTS FOR CANCER', SURGERY GYNECOLOGY & OBSTETRICS, 150 12-16 (1980)
|
|
|
1980 |
Vingelis V, Ashman LK, Kotlarski I, 'Factors affecting the ability of various strains of Enterobacteriaceae to induce tumour resistance in mice', Australian Journal of Experimental Biology and Medical Science, 58 123-131 (1980)
Primary infection of mice with Salmonella enteritidis 11RX (11RX) confers resistance to challenge with 104 LD50 doses of Ehrlich Ascites tumour (EAT). A lipopolysaccharide-free pr... [more]
Primary infection of mice with Salmonella enteritidis 11RX (11RX) confers resistance to challenge with 104 LD50 doses of Ehrlich Ascites tumour (EAT). A lipopolysaccharide-free protein extract of 11RX is capable of eliciting delayed type hypersensitivity (DTH) reactions in these mice and of 'recalling' tumour resistance in long-term 11RX immunised mice, which no longer exhibit any resistance to tumour challenge. In the present study, we have examined the ability of five other strains of Enterobacteriaceae to induce similar effects. Primary i.p. injection of S. chester, S. luton or S. typhimurium G30 into mice resulted in persisting infections and the induction of peritoneal exudate cells (PEC) which were tumouricidal in vitro. DTH reactions could also be elicited in these animals with protein extracts of the homologous or the 11RX strain of salmonella. S. friedenan and E. coli K12, which did not persist in mice, did not elicit tumouricidal PEC and did not sensitize mice for DTH reactions. However, protein extracts from all the five strains could elicit tumouricidal PEC and DTH reactions in long-term 11RX-immunised mice (but not in normal mice). The results imply that a wide range of Enterobacteriaceae may possess antigen(s) which can be involved in tumour resistance, provided that these antigen(s) are presented in such a way that a cellular immune response develops.
|
|
|
1980 |
Ashman LK, Goh DHB, Kotlarski I, 'Involvement of donor lymphoreticular cells in the rejection of B16 melanoma by allogeneic mice', Australian Journal of Experimental Biology and Medical Science, 58 159-166 (1980)
B16 melanoma maintained by in vivo passage in syngeneic (C57Bl/6) mice was rejected when transplanted into H-2 incompatible BALB/c mice. However, after passage in tissue culture t... [more]
B16 melanoma maintained by in vivo passage in syngeneic (C57Bl/6) mice was rejected when transplanted into H-2 incompatible BALB/c mice. However, after passage in tissue culture the tumour grew in BALB/c mice and, in the case of intraperitoneal (i.p.) inoculation, was fatal. Administration of lymphoreticular cells (resident peritoneal cells, PC) bearing C57B1/6 alloantigens at the same time as the cultured tumour prevented or greatly diminished tumour growth in BALB/c mice. This occurred when the PC were given either at the same site as the tumour or at a remote site, implying that tumour rejection involved specific sensitization of the BALB/c mice to C57Bl/6 alloantigens presented on the PC. Conversely, administration of PC from a strain (C3H) with a H-2 haplotype unrelated to either the tumour or the allogeneic recipient mice diminished tumour growth when given at the same site, but had no effect when given at a remote site. This result is consistent with the involvement in sensitization of a soluble factor produced by or in response to the allogeneic PC, which is not antigen-specific, and which operates over a short range. These results indicate that, as for mouse thyroid allograft rejection (Lafferty and Woolnough, 1977), rejection of a B16 melanoma allograft was dependent on the presence of donor stimulator cells of lymphoreticular origin. The implications for the generation of immunity in syngeneic and autochthonous tumour systems are discussed.
|
|
|
1979 |
DEYOUNG NJ, ASHMAN LK, LUDBROOK J, MARSHALL VR, 'CANCER DISCRIMINATORY ABILITY OF THE CARCINOEMBRYONIC ANTIGEN-ASSAY, PHOSPHOHEXOSE ISOMERASE ACTIVITY AND ERYTHROCYTE SEDIMENTATION-RATE', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 49 145-146 (1979) |
|
|
1979 |
ASHMAN LK, KOTLARSKI I, 'INHIBITION OF THE GROWTH OF LEWIS LUNG-CARCINOMA IN SYNGENEIC MICE BY SALMONELLA ANTIGENS', AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 57 637-639 (1979)
|
|
|
1979 |
ASHMAN LK, COOK MG, KOTLARSKI I, 'PROTECTIVE EFFECT OF ORAL SALMONELLA-ENTERITIDIS 11RX INFECTION AGAINST COLON-TUMOR INDUCTION BY 1,2-DIMETHYLHYDRAZINE IN MICE', CANCER RESEARCH, 39 2768-2771 (1979)
|
|
|
1979 |
Ashman LK, Kotlarski I, 'Inhibition of the growth of Lewis lung carcinoma in syngeneic mice by Salmonella antigens', Australian Journal of Experimental Biology and Medical Science, 57 637-639 (1979)
Administration of a protein antigen preparation from Salmonella enteritidis 11RX at the site of challenge with Lewis lung carcinoma inhibited tumour development in mice previously... [more]
Administration of a protein antigen preparation from Salmonella enteritidis 11RX at the site of challenge with Lewis lung carcinoma inhibited tumour development in mice previously immunised with live bacteria, but not control mice. The kinetics of tumour growth indicated that the inhibition of tumour development was due to a reduction of the initial tumour inoculum rather than the development of specific antitumour immunity.
|
|
|
1978 |
DEYOUNG NJ, ASHMAN LK, 'PHYSICOCHEMICAL AND IMMUNOCHEMICAL PROPERTIES OF CARCINOEMBRYONIC ANTIGEN (CEA) FROM DIFFERENT TUMOR SOURCES', AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 56 321-331 (1978)
|
|
|
1978 |
ASHMAN LK, KOTLARSKI I, 'EFFECT OF SALMONELLA-ENTERITIDIS 11RX INFECTION ON 2-STAGE SKIN CARCINOGENESIS IN MICE', AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 56 695-701 (1978)
|
|
|
1978 |
De Young NJ, Ashman LK, 'Physicochemical and immunochemical properties of carcinoembryonic antigens (CEA) from different tumour sources', Australian Journal of Experimental Biology and Medical Science, 56 321-331 (1978)
The physical, chemical and immunochemical properties of carcinoembryonic antigen (CEA) purified from hepatic metastases of eight tumours, originating in the colon (6), stomach (1)... [more]
The physical, chemical and immunochemical properties of carcinoembryonic antigen (CEA) purified from hepatic metastases of eight tumours, originating in the colon (6), stomach (1) and lung (1), have been examined. Differences were observed in the overall molecular charge, and also in the carbohydrate composition of the different preparations (both total % carbohydrate, and mole % of the individual sugars). Negligible differences in amino acid composition were found. Gel filtration analysis of these CEA preparations and an additional four partially purified preparations (from pancreatic, hepatic, breast and oesophageal tumour tissues) revealed a single CEA-active peak of similar molecular weight (about 200,000-300,000 daltons) in all preparations. Radioimmunoassay data for the twelve CEA preparations indicated that all preparations contain the same antigenic determinants, as detected by our antiserum, but that there are differences in the expression of these determinants in different preparations.
|
|
|
1978 |
Ashman LK, Kotlarski I, 'Effect of Salmonella enteritidis 11RX infection on two-stage skin carcinogenesis in mice', Australian Journal of Experimental Biology and Medical Science, 56 695-701 (1978)
S. enteritidis 11RX infection inhibits the growth of a number of transplantable tumors in mice. In addition, oral infection of mice with S. enteritidis 11RX inhibits colon carcino... [more]
S. enteritidis 11RX infection inhibits the growth of a number of transplantable tumors in mice. In addition, oral infection of mice with S. enteritidis 11RX inhibits colon carcinogenesis by 1,2 dimethylhydrazine. This study has examined the effect of S. enteritidis 11RX infection on two-stage skin carcinogenesis in mice using 7,12 dimethylbenz(a)anthracene (DMBA) as initiator and croton oil as promotor. No protection was observed in either LACA or (BALB/c x C57B1/6J)F1 mice when live 11RX was repeatedly administered i.v. during promotion. When a protein antigen extract from S. enteritidis 11RX was administered i.v. to previously immunized mice during skin carcinogenesis, significant protection was observed both in terms of the number of mice with papillomas and the number of papillomas per mouse. However, the protection was weak and transient. LACA mice were much more susceptible to skin carcinogenesis by DMBA and croton oil than were (BALB/c x C57B1/6J)F1 mice. A preliminary study indicated that BALB/c, C57B1 and CBA mice were also relatively resistant to skin carcinogenesis.
|
|
|
1977 |
ASHMAN LK, LUDBROOK J, MARSHALL VR, 'COMPARISON OF WHOLE PLASMA AND PERCHLORIC ACID-EXTRACTED PLASMA ASSAYS FOR CARCINOEMBRYONIC ANTIGEN', CLINICA CHIMICA ACTA, 74 77-84 (1977)
|
|
|
1977 |
ASHMAN LK, DEYOUNG NJ, 'IMMUNOADSORBENT PURIFICATION OF CARCINOEMBRYONIC ANTIGEN', IMMUNOCHEMISTRY, 14 329-336 (1977)
|
|
|
1975 |
ASHMAN LK, DEYOUNG NJ, GEARY D, LUDBROOK J, 'CARCINOEMBRYONIC ANTIGEN LEVELS IN PLASMA OF CANCER-PATIENTS AND OF CANCER-FREE HOSPITAL INPATIENTS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 45 109-109 (1975) |
|
|
1975 |
ASHMAN LK, KEECH DB, 'KINETIC APPROACH TO DEFINING ROLE OF CHEMICALLY MODIFIABLE RESIDUES AT ACTIVE-SITES OF ENZYMES', AUSTRALIAN JOURNAL OF BIOLOGICAL SCIENCES, 28 379-387 (1975)
|
|
|
1975 |
ASHMAN LK, KEECH DB, 'SHEEP KIDNEY PYRUVATE-CARBOXYLASE - STUDIES ON COUPLING OF ADENOSINE-TRIPHOSPHATE HYDROLYSIS AND CO2 FIXATION', JOURNAL OF BIOLOGICAL CHEMISTRY, 250 14-21 (1975)
|
|
|
1975 |
ASHMAN LK, DEYOUNG NJ, 'IMMUNOADSORBENT PURIFICATION OF A GLYCOPROTEIN FROM HUMAN TUMOR TISSUE', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 8 40-40 (1975) |
|
|
1975 |
ASHMAN LK, 'PURIFICATION OF CARCINOEMBRYONIC ANTIGEN BY AFFINITY CHROMATOGRAPHY USING IMMOBILIZED ANTIBODIES', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2 82-82 (1975) |
|
|
1975 |
ASHMAN LK, LUDBROOK J, MARSHALL VR, 'PROBABILISTIC APPLICATION OF PLASMA CARCINOEMBRYONIC ANTIGEN ASSAY IN CANCER-PATIENTS', BRITISH MEDICAL JOURNAL, 2 721-724 (1975)
|
|
|
1974 |
ASHMAN LK, KEECH DB, 'ANALOG STUDIES OF PYRUVATE-CARBOXYLASE REACTION-MECHANISM', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 7 18-18 (1974) |
|
|
1973 |
ASHMAN LK, WALLACE JC, KEECH DB, 'DESENSITIZATION OF PYRUVATE CARBOXYLASE AGAINST ACETYL COA STIMULATION BY CHEMICAL MODIFICATION', BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 51 924-931 (1973)
|
|
|
1973 |
ASHMAN LK, KEECH DB, 'DESENSITIZATION OF ALLOSTERIC ACTIVATION OF PYRUVATE CARBOXYLASE', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, 6 12-12 (1973) |
|
|
1972 |
ASHMAN LK, ATWELL JL, 'AMP DEAMINASE FROM RABBIT SKELETAL-MUSCLE - EFFECT OF MONOVALENT CATIONS ON CATALYTIC ACTIVITY AND MOLECULAR-WEIGHT', BIOCHIMICA ET BIOPHYSICA ACTA, 258 618-+ (1972)
|
|
|
1972 |
ASHMAN LK, WALLACE JC, KEECH DB, NIELSEN J, 'SHEEP KIDNEY PYRUVATE CARBOXYLASE - STUDIES ON ITS ACTIVATION BY ACETYL COENZYME-A AND CHARACTERISTICS OF ITS ACETYL COENZYME-A INDEPENDENT REACTION', JOURNAL OF BIOLOGICAL CHEMISTRY, 247 5818-& (1972)
|
|
|